Argireline vs Matrixyl
A side-by-side research comparison of Argireline and Matrixyl across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | Matrixyl |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | Signals through TGF-B pathway to stimulate fibroblast production of collagen I, III, IV, fibronectin, and hyaluronic acid. Palmitoyl chain enhances penetration. |
| Molecular weight | 889 Da | 802.1 Da |
| Half-life | 8-12 hours (topical) | 6-12 hours (topical depot) |
| Bioavailability | Moderate (topical) | Moderate (topical) |
| Typical dose | 5-10% solution | 2-8% in serum/cream |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical | Topical |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
Matrixyl reported benefits
- Stimulates collagen I, III, IV
- Reduces wrinkle depth up to 45%
- Increases skin thickness
- Improves firmness
- Enhances hydration
Related comparisons
Research and educational reference only. Not medical advice.